Citigroup’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $806K | Buy |
27,131
+20
| +0.1% | +$598 | ﹤0.01% | 3248 |
|
|
2025
Q4 | $1.04M | Buy |
27,111
+14,790
| +120% | +$481K | ﹤0.01% | 3120 |
|
|
2025
Q3 | $294K | Sell |
12,321
-55,232
| -82% | -$1.04M | ﹤0.01% | 3820 |
|
|
2025
Q2 | $1,000K | Sell |
67,553
-108,693
| -62% | -$1.8M | ﹤0.01% | 3194 |
|
|
2025
Q1 | $3.16M | Buy |
176,246
+39,090
| +29% | +$793K | ﹤0.01% | 2310 |
|
|
2024
Q4 | $2.39M | Buy |
137,156
+79,555
| +138% | +$1.41M | ﹤0.01% | 2666 |
|
|
2024
Q3 | $806K | Buy |
57,601
+12,648
| +28% | +$132K | ﹤0.01% | 3432 |
|
|
2024
Q2 | $370K | Sell |
44,953
-462,080
| -91% | -$3.11M | ﹤0.01% | 3574 |
|
|
2024
Q1 | $3.91M | Buy |
507,033
+294,970
| +139% | +$2.49M | ﹤0.01% | 1899 |
|
|
2023
Q4 | $1.91M | Sell |
212,063
-121,308
| -36% | -$883K | ﹤0.01% | 2284 |
|
|
2023
Q3 | $2.98M | Buy |
333,371
+67,909
| +26% | +$958K | ﹤0.01% | 1729 |
|
|
2023
Q2 | $4.08M | Sell |
265,462
-96,609
| -27% | -$1.76M | ﹤0.01% | 1628 |
|
|
2023
Q1 | $8.14M | Buy |
362,071
+216,863
| +149% | +$4.61M | 0.01% | 1252 |
|
|
2022
Q4 | $3.05M | Sell |
145,208
-46,176
| -24% | -$979K | ﹤0.01% | 1760 |
|
|
2022
Q3 | $4.71M | Buy |
191,384
+54,490
| +40% | +$1.41M | ﹤0.01% | 1593 |
|
|
2022
Q2 | $3.32M | Buy |
136,894
+107,049
| +359% | +$2.69M | ﹤0.01% | 1763 |
|
|
2022
Q1 | $770K | Sell |
29,845
-114,539
| -79% | -$3.04M | ﹤0.01% | 3182 |
|
|
2021
Q4 | $4.48M | Sell |
144,384
-91,443
| -39% | -$2.58M | ﹤0.01% | 1920 |
|
|
2021
Q3 | $5.72M | Buy |
235,827
+25,308
| +12% | +$465K | ﹤0.01% | 1730 |
|
|
2021
Q2 | $3.07M | Buy |
210,519
+85,578
| +68% | +$1.69M | ﹤0.01% | 2318 |
|
|
2021
Q1 | $3.12M | Buy |
124,941
+112,971
| +944% | +$3.12M | ﹤0.01% | 2173 |
|
|
2020
Q4 | $326K | Buy |
11,970
+7,370
| +160% | +$172K | ﹤0.01% | 4589 |
|
|
2020
Q3 | $85K | Sell |
4,600
-27,214
| -86% | -$529K | ﹤0.01% | 5240 |
|
|
2020
Q2 | $650K | Sell |
31,814
-2,876
| -8% | -$45.8K | ﹤0.01% | 3986 |
|
|
2020
Q1 | $507K | Buy |
34,690
+19,327
| +126% | +$291K | ﹤0.01% | 3859 |
|
|
2019
Q4 | $218K | Sell |
15,363
-112,692
| -88% | -$1.44M | ﹤0.01% | 5115 |
|
|
2019
Q3 | $1.48M | Buy |
128,055
+23,117
| +22% | +$382K | ﹤0.01% | 3190 |
|
|
2019
Q2 | $2.11M | Buy |
104,938
+80,777
| +334% | +$1.59M | ﹤0.01% | 2791 |
|
|
2019
Q1 | $546K | Sell |
24,161
-59,237
| -71% | -$1.31M | ﹤0.01% | 4091 |
|
|
2018
Q4 | $1.89M | Buy |
83,398
+58,641
| +237% | +$1.46M | ﹤0.01% | 2734 |
|
|
2018
Q3 | $711K | Buy |
24,757
+4,168
| +20% | +$119K | ﹤0.01% | 3866 |
|
|
2018
Q2 | $562K | Buy |
20,589
+14,826
| +257% | +$395K | ﹤0.01% | 3969 |
|
|
2018
Q1 | $129K | Sell |
5,763
-33,221
| -85% | -$791K | ﹤0.01% | 5380 |
|
|
2017
Q4 | $822K | Buy |
38,984
+20,351
| +109% | +$465K | ﹤0.01% | 3552 |
|
|
2017
Q3 | $464K | Sell |
18,633
-7,177
| -28% | -$158K | ﹤0.01% | 4199 |
|
|
2017
Q2 | $500K | Buy |
25,810
+5,082
| +25% | +$92.2K | ﹤0.01% | 3992 |
|
|
2017
Q1 | $383K | Sell |
20,728
-85,642
| -81% | -$1.68M | ﹤0.01% | 4089 |
|
|
2016
Q4 | $2.01M | Buy |
106,370
+89,322
| +524% | +$1.83M | ﹤0.01% | 2936 |
|
|
2016
Q3 | $382K | Buy |
17,048
+9,714
| +132% | +$185K | ﹤0.01% | 4137 |
|
|
2016
Q2 | $131K | Sell |
7,334
-23,905
| -77% | -$387K | ﹤0.01% | 4857 |
|
|
2016
Q1 | $427K | Buy |
31,239
+27,986
| +860% | +$425K | ﹤0.01% | 4291 |
|
|
2015
Q4 | $63K | Sell |
3,253
-17,722
| -84% | -$354K | ﹤0.01% | 5752 |
|
|
2015
Q3 | $425K | Buy |
20,975
+16,474
| +366% | +$488K | ﹤0.01% | 3902 |
|
|
2015
Q2 | $149K | Sell |
4,501
-467
| -9% | -$12.8K | ﹤0.01% | 4689 |
|
|
2015
Q1 | $119K | Sell |
4,968
-4,267
| -46% | -$65.1K | ﹤0.01% | 4894 |
|
|
2014
Q4 | $113K | Buy |
9,235
+8,458
| +1,089% | +$87.5K | ﹤0.01% | 5151 |
|
|
2014
Q3 | $7K | Buy |
777
+418
| +116% | +$4.92K | ﹤0.01% | 6428 |
|
|
2014
Q2 | $4K | Sell |
359
-1,640
| -82% | -$22.2K | ﹤0.01% | 6552 |
|
|
2014
Q1 | $43K | Buy |
+1,999
| New | +$30.7K | ﹤0.01% | 5583 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Citigroup's TVTX Position: Q1 2026 in Review
Citigroup increased its Travere Therapeutics (TVTX) stake by 0.07% in Q1 2026, buying an estimated $598 and bringing the position to 27,131 shares worth $806K. The position accounts for ﹤0.01% of the portfolio, ranked #3248.
Citigroup first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $8.14M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Citigroup held 27,131 shares of Travere Therapeutics worth $806K as of Q1 2026.
- Citigroup bought 20 Travere Therapeutics shares in Q1 2026, an estimated $598.
- Travere Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3248 holding.
- Citigroup first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
- Citigroup's Travere Therapeutics position peaked at $8.14M in Q1 2023.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.